RxDoctor Payments Data

Ahmad El Kouzi, MD

Neurology · Springfield, ILNPI 1861834152

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by AbbVie at 46.3% of the total. Reporting peaked in 2021 at $2,515 and has fallen 93.3% since, to $169 in 2025.

$7,177in general payments, 2019–2025

Across 35 payments — averaging $205.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Sage Therapeutics, LLC$1K
  • Boston Scientific$1K
  • Medtronic$573
  • MDD US Operations, LLC$183
  • Abbott$136
  • plus $138 from 2 others
$260,648in research payments, 2019–2025

Across 25 payments — averaging $10,426 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$219K
  • Sage Therapeutics, LLC$31K
  • AbbVie$11K

What the payments were for

  • Consulting fees$3,05042%
  • Travel & lodging$2,10729%
  • Food & beverage$2,02028%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,177 in reported general payments places this provider in the 75th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$127,920
Medicare patients
297
Services billed
10,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa18$21,065
Carbidopa-LevodopaCarbidopa/Levodopa216$6,179
Lacosamide18$3,792
Carbidopa-Levodopa ErCarbidopa/Levodopa38$2,723
Rasagiline Mesylate18$2,210
Primidone31$715
Baclofen18$501
Pregabalin13$488
Gabapentin22$418
Ropinirole Hcl15$349
Donepezil Hcl21$325
Memantine Hcl11$264
Clonazepam18$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$92$21,06518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 790 neurology providers in Illinois.

Other neurology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →